CLINICAL_TRIALS
ClinicalTrials.gov record update
A Multicenter, Open Label, Randomized Phase II Study Comparing Daratumumab Combined With Bortezomib-Cyclophosphamide-dexamethasone (Dara-VCd) Versus the Association of Bortezomib-Thalidomide-dexamethasone (VTd) as Pre Transplant Induction and Post Transplant Consolidation, Both Followed by a Maintenance Phase With Ixazomib Alone or in Combination With Daratumumab, in Newly Diagnosed Multiple Myeloma (MM) Young Patients Eligible for Autologous Stem Cell Transplantation
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT03896737
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:27:28.700587+00:00
- Published At
- 2025-08-11T00:00:00+00:00
- Record Updated At
- 2025-08-11
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Multiple Myeloma"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-08-11"- protocolSection.identificationModule.nctId
"NCT03896737"- protocolSection.identificationModule.officialTitle
"A Multicenter, Open Label, Randomized Phase II Study Comparing Daratumumab Combined With Bortezomib-Cyclophosphamide-dexamethasone (Dara-VCd) Versus the Association of Bortezomib-Thalidomide-dexamethasone (VTd) as Pre Transplant Induction and Post Transplant Consolidation, Both Followed by a Maintenance Phase With Ixazomib Alone or in Combination With Daratumumab, in Newly Diagnosed Multiple Myeloma (MM) Young Patients Eligible for Autologous Stem Cell Transplantation"- protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.